BRNS vs CADL

Barinthus Biotherapeutics plc vs Candel Therapeutics, Inc. — Valuation Comparison 2026

BRNS

Biotechnology
Barinthus Biotherapeutics plc
Quality
6.0
out of 10
Value Trap
24
SAFE
Price
$0.68
Last close
Models
9/13
Active
VS

CADL

Biotechnology
Candel Therapeutics, Inc.
Quality
4.4
out of 10
Value Trap
38
LOW
Price
$8.09
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType BRNS Fair ValueBRNS Upside CADL Fair ValueCADL Upside
Bayesian DCF Intrinsic $0.94 +37.8% $3.35 -58.6%
First Chicago Scenario $0.26 -63.5% $11.98 +56.8%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $1.83 +167.5% $2.44 -69.9%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for BRNS vs CADL — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BRNS vs CADL — Which Stock Is More Undervalued?

BRNS scores higher with a 6.0/10 quality rating vs CADL's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Barinthus Biotherapeutics plc (BRNS) and Candel Therapeutics, Inc. (CADL) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BRNS currently trades at $0.68 with a QOC of 6.0/10, while CADL trades at $8.09 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).